Table 2.
Baseline demographic and clinical characteristic of patients treated with fingolimod and natalizumab.
| Characteristic | All Patients n = 336 | Fingolimod | Natalizumab | p (Mann–Whitney U) |
|---|---|---|---|---|
| Age, years, mean (SD) | 38.7 (10.0) | 39.4 (10.5) | 37.6 (9.0) | 0.133 |
| Female, n (%) | 222 (66.1) | 135 (67.16) | 87 (64.4) | p = 0.15 |
| Onset age, years (SD) | 27.5 (9.2) | 27.6 (9.8) | 27.2 (8.1) | 0.995 |
| Disease duration until 1/November/2018, years (SD) | 10.7 (5.4) | 11.2 (5.7) | 9.8 (4.7) | 0.094 |
| Mean ARR before initiation of treatment, number (SD) | 2.0 (0.6) | 2.0 (0.7) | 2.1 (0.6) | 0.206 |
| Mean EDSS before initiation of treatment, points (SD) | 3.26 (1.3) | 3.3 (1.3) | 3.2 (1.4) | 0.598 |
| Number of T2 lesions on MRI one year before initiation of treatment, number (SD) | 19.4 (6.2) | 19.3 (6.5) | 19.6 (5.6) | 0.455 |
| Number of Gd+ lesions on MRI one year before initiation of treatment, number (SD) | 2.3 (3.7) | 2.2 (3.4) | 2.5 (4.1) | 0.366 |
| Patients treated | 336 | 201 (59.8) | 135 (40.2) |
ARR, annualized relapse rate; EDSS, expanded disability status scale; Gd+, gadolinium; MRI, magnetic resonance imaging; SD, standard deviation.